Update on antiglomerular basement membrane disease

Current Opinion in Rheumatology

Volumn 23, Issue 1, 2011, Pages 32-37

  Peto, Philippa ^a   Salama, Alan D ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

autoantibodies; autoimmunity; glomerular basement membrane; glomerulonephritis; T cells

Indexed keywords

ALEMTUZUMAB; COLLAGEN TYPE 4;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTIGLOMERULAR BASEMENT MEMBRANE DISEASE; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; COLLAGEN TYPE IV; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, CELLULAR; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES;

EID: 78650512266     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328341009f     Document Type: Article

References (69)

1. Salama AD, Levy JB, Lightstone L, Pusey CD. Goodpastures disease. Lancet 2001; 358:917-920.
2. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033-1042.
3. Yang R, Hellmark T, Zhao J, et al. Antigen and epitope specificity of antiglomerular basement membrane antibodies in patients with goodpasture disease with or without antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 2007; 18:1338-1343. (Pubitemid 46536921)
4. Rutgers A, Slot M, van Paassen P, et al. Coexistence of antiglomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46:253-262.
5. Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535-1540.
6. Lindic J, VizjakA, Ferluga D, et al. Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. Ther Apher Dial 2009; 13:278-281.
7. Zhao J, Yang R, Cui Z, et al. Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract 2007; 107:c56-c62.
8. Lerner RA, Glassock RJ, Dixon FJ. The role of antiglomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 1967; 126:989-1004.
9. Kalluri R, Danoff TM, Okada H, Neilson EG. Susceptibility to antiglomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 1997; 100:2263-2275.
10. Wilson CB, Dixon FJ. Antiglomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973; 3:74-89.
11. Peters DK, Rees AJ, Lockwood CM, Pusey CD. Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc 1982; 14:513-521.
12. Salama AD, Dougan T, Levy JB, et al. Goodpasture's disease in the absence of circulating antiglomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 2002; 39:1162-1167.
13. Damoiseaux J, Vaessen M, Knapen Y, et al. Evaluation of the FIDIS vasculitis multiplex immunoassay for diagnosis and follow-up of ANCA-associated vasculitis and Goodpasture's disease. Ann N Y Acad Sci 2007; 1109:454-463.
14. Sinico RA, Radice A, Corace C, et al. Antiglomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrol Dial Transplant 2006; 21:397-401.
15. Bowman C, Lockwood CM. Clinical application of a radio-immunoassay for auto-antibodies to glomerular basement membrane. J Clin Lab Immunol 1985; 17:197-202.
16. Szczech LA, Anderson A, Ramers C, et al. The uncertain significance of antiglomerular basement membrane antibody among HIV-infected persons with kidney disease. Am J Kidney Dis 2006; 48:e55-e59.
17. Cui Z, Wang HY, Zhao MH. Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int 2006; 69:894-899.
18. Yang R, Cui Z, Hellmark T, et al. Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin Immunol 2007; 124:207-212.
19. Kalluri R, Wilson CB, Weber M, etal. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 1995; 6:1178-1185.
20. Turner N, Mason PJ, Brown R, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest 1992; 89:592-601.
21. Cashman SJ, Pusey CD, Evans DJ. Extraglomerular distribution of immunor-eactive Goodpasture antigen. J Pathol 1988; 155:61-70.
22. Dehan P, Weber M, Zhang X, etal. Sera from patients with anti-GBM nephritis including goodpasture syndrome show heterogenous reactivity to recombinant NC1 domain of type IV collagen alpha chains. Nephrol Dial Transplant 1996; 11:2215-2222.
23. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Good-pasture autoantigen in anti-GBM nephritis. N Engl J Med 2010;363:343-354.
24. Segelmark M, Butkowski R, Wieslander J. Antigen restriction and IgG subclasses among anti-GBM autoantibodies. Nephrol Dial Transplant 1990; 5:991-996.
25. Zhao J, Yan Y, Cui Z, etal. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol 2009; 70:425-429.
26. Hellmark T, Segelmark M, Unger C, et al. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int 1999; 55:936-944.
27. Leinonen A, Netzer KO, Boutaud A, etal. Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. Kidney Int 1999; 55:926-935.
28. Ryan JJ, Mason PJ, Pusey CD, Turner N. Recombinant alpha-chains of type IV collagen demonstrate that the amino terminal of the Goodpasture autoantigen is crucial for antibody recognition. Clin Exp Immunol 1998; 113:17-27.
29. Meyers KE, Christensen M, Madaio MP. Modeling of human anti-GBM anti-body-alpha3(IV)NC1 interactions predicts antigenic cross-linking through contact of both heavy chains with repeating epitopes on alpha3(IV)NC1.Am J Nephrol 2009; 30:474-480.
30. Borza DB, Netzer KO, Leinonen A, et al. The goodpasture autoantigen: identification of multiple cryptic epitopes on the NC1 domain of thealpha3(IV) collagen chain. J Biol Chem 2000; 275:6030-6037.
31. Xenocostas A, Jothy S, Collins B, et al. Antiglomerular basement membrane glomerulonephritis after extracorporeal shockwave lithotripsy. Am J Kidney Dis 1999; 33:128-132.
32. Kalluri R, Cantley LG, Kerjaschki D, Neilson EG. Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome. J Biol Chem 2000; 275:20027-20032.
33. Troxell ML, Higgins JP, Sibley RK. Glomerular and tubular basement membrane calcinosis: case report and literature review. Am J Kidney Dis 2006; 47:e23-e26.
34. Bolton WK, Chandra M, Tyson TM, et al. Transfer of experimental glomerulonephritis in chickens by mononuclear cells. Kidney Int 1988; 34:598-610.
35. Hopfer H, Maron R, Butzmann U, et al. The importance of cell-mediated immunity in the course and severity of autoimmune antiglomerular basement membrane disease in mice. FASEB J 2003; 17:860-868.
36. Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to antiglomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int 1997; 51:222-229.
37. Bolton WK, Innes DJ Jr, Sturgill BC, Kaiser DL. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int 1987; 32:869-876.
38. Nolasco FE, Cameron JS, Hartley B, et al. Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies. Kidney Int 1987; 31:1160-1166.
39. Reynolds J, Tam FW, Chandraker A, et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 2000; 105:643-651.
40. Reynolds J, Cashman SJ, Evans DJ, Pusey CD. Cyclosporin A in the prevention and treatment of experimental autoimmune glomerulonephritis in the brown Norway rat. Clin Exp Immunol 1991; 85:28-32.
41. Ooi JD, Phoon RK, Holdsworth SR, Kitching AR. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 2009; 20:980-989.
42. Reynolds J, Pusey CD. Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol 2001; 12:61-70.
43. Wu J, Hicks J, Ou C, et al. Glomerulonephritis induced by recombinant collagen IV alpha 3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: a potential T cell-mediated mechanism. J Immunol 2001; 167:2388-2395.
44. Derry CJ, Ross CN, Lombardi G, et al. Analysis of T cell responses to the autoantigen in Goodpasture's disease. Clin Exp Immunol 1995; 100:262-268.
45. Zou J, Hannier S, Cairns LS, et al. Healthy individuals have Goodpasture autoantigen-reactive T cells. J Am Soc Nephrol 2008; 19:396-404.
46. Salama AD, Chaudhry AN, Ryan JJ, etal. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol 2001; 12:1908-1915.
47. Wong D, Phelps RG, Turner AN. The Goodpasture antigen is expressed in the human thymus. Kidney Int 2001; 60:1777-1783.
48. Arends J, Wu J, Borillo J, et al. T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 2006; 176:1252-1258.
49. Phelps RG, Jones VL, Coughlan M, et al. Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences. J Biol Chem 1998; 273:11440-11447.
50. Phelps RG, Turner AN, Rees AJ. Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15. J Biol Chem 1996; 271: 18549-18553.
51. Zou J, Henderson L, Thomas V, et al. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J Am Soc Nephrol 2007; 18:771-779.
52. Clatworthy MR, Wallin EF, Jayne DR. Antiglomerular basement membrane disease after alemtuzumab. N Engl J Med 2008; 359:768-769.
53. Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56:1638-1653.
54. Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1 *1501 allele is prevalent among Japanese patients with antiglomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant 2008; 23:3126-3129.
55. Phelps RG, Jones V, Turner AN, Rees AJ. Properties of HLA class II molecules divergently associated with Goodpasture's disease. Int Immunol 2000; 12:1135-1143.
56. Reynolds J, Mavromatidis K, Cashman SJ, et al. Experimental autoimmune glomerulonephritis (EAG) induced by homologous and heterologous glomerular basement membrane in two substrains of Wistar-Kyoto rat. Nephrol Dial Transplant 1998; 13:44-52.
57. Reynolds J, Cook PR, Ryan JJ, etal. Segregation of experimental autoimmune glomerulonephritis as a complex genetic trait and exclusion of Col4a3 as a candidate gene. Exp Nephrol 2002; 10:402-407.
58. Nakamura A, Yuasa T, Ujike A, et al. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 2000; 191:899-906.
59. Zhou XJ, Lv JC, Yu L, et al. FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. Nephrol Dial Transplant 2010; 25:97-101.
60. Tarzi RM, Davies KA, Claassens JW, et al. Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis. Am J Pathol 2003; 162:1677-1683.
61. Zhou XJ, Lv JC, Bu DF, et al. Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. Int Immunol 2010; 22:45-51.
62. Rees AJ, Lockwood CM, Peters DK. Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. Br Med J 1977; 2:723-726.
63. Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture's disease. Am J Kidney Dis 1996; 27:573-578.
64. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and antiglomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med 1992; 21:141-153.
65. Yaqoob M, King A, McClelland P, et al. Relationship between hydrocarbon exposure and nephropathology in primary glomerulonephritis. Nephrol Dial Transplant 1994; 9:1575-1579.
66. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61:922-924.
67. Wechsler E, Yang T, Jordan SC, et al. Antiglomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol 2008; 4:167-171.
68. Kiykim AA, Horoz M, Gok E. Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid. Intern Med 2010; 49:577-580.
69. Merkel F, Weber M. Successful use of cyclosporin A in progressive antiglomerular basement membrane nephritis. Nephrol Dial Transplant 2000; 15:1714-1715.